Regeneron R2810-ONC-2045
Condition: Lung
Lung
Regeneron R2810-ONC-2045 – A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) In Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy In First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
Who’s Eligible/Study Details:
- Age 18+
- Patients with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment, or stage IV (metastatic) disease who received no prior systemic treatment for recurrent or metastatic NSCLC.
- Availability of an archival or on-study obtained formalin-fixed, paraffin-embedded tumor tissue sample.
- Expression of PD-L1 in ≥ 50% of tumor cells, confirmed by a central laborator
If you would like more information please contact clinical trials research coordinator at DJL Research in Charlotte 704-247-9179, x-207